| Literature DB >> 35630605 |
Kai Bin Liew1, Long Chiau Ming2, Bey-Hing Goh3,4, Kok Khiang Peh5.
Abstract
A fast melt tablet (FMT) is well regarded as an alternative delivery system that might help resolve a patient's non-compliance issue. The main objective of this study was to develop a cocoa butter-based FMT. Additives, namely 5-15% of PEG 6000, beeswax, paraffin wax, and corn starch, were incorporated into the cocoa butter-based FMT to study the effects of these additives with the physical characteristic of a cocoa butter FMT. An optimum-based formulation was chosen according to the desired hardness and disintegration time and the taste masking property achieved with the model drug-dapoxetine. The analysis demonstrated that incorporating beeswax (15%) and paraffin wax (15%) could prolong the disintegration time by at least two-fold. On the contrary, the presence of corn starch was found to cause an increase in the hardness and reduction of the disintegration time. The disintegration mechanism might be presumed due to the synergistic effect of starch swelling and cocoa butter melting. The hardness value and in vitro disintegration time of the optimum formulation were recorded at 2.93 ± 0.22 kg and 151.67 ± 6.98 s. In terms of dissolution, 80% of dapoxetine was released within 30 min and the dissolution profile was comparable to the innovator product. The formulation was palatable and stable for at least 1 year. The exposure of the FMT formulation at 30 °C for 12 months was reported to be stable. Along with the sound palatability profile and high drug load capacity, the current formulation possesses the desired characteristics to be scaled up and marketed.Entities:
Keywords: PEG 6000; cocoa butter; dapoxetine; fast melt tablet; starch; wax
Mesh:
Substances:
Year: 2022 PMID: 35630605 PMCID: PMC9143478 DOI: 10.3390/molecules27103128
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Various cocoa butter-based formulations.
| Ingredient | Formulation (mg) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C1 | C2 | C3 | C4 | C5 | C6 | C7 | C8 | C9 | C10 | C11 | C12 | C13 | |
| Cocoa butter | 500 | 475 | 450 | 425 | 475 | 450 | 425 | 475 | 450 | 425 | 475 | 450 | 425 |
| PEG 6000 | - | 25 | 50 | 75 | - | - | - | - | - | - | - | - | - |
| Beeswax | - | - | - | - | 25 | 50 | 75 | - | - | - | - | - | - |
| Paraffin wax | - | - | - | - | - | - | - | 25 | 50 | 75 | - | - | - |
| Corn starch | - | - | - | - | - | - | - | - | - | - | 25 | 50 | 75 |
| Total | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 |
| Additive (%) | 0 | 5 | 10 | 15 | 5 | 10 | 15 | 5 | 10 | 15 | 5 | 10 | 15 |
Hardness and statistical analysis results of various ODT formulations/additives.
| Formulation | Hardness (kg) |
|---|---|
| C1 (0% additive) | 0.59 ± 0.04 |
| C2 (5% PEG6000) | 0.61 ± 0.04 |
| C3 (10% PEG6000) | 0.71 ± 0.04 |
| C4 (15% PEG6000) | 0.78 ± 0.06 |
| C5 (5% Beeswax) | 0.59 ± 0.03 |
| C6 (10% Beeswax) | 0.64 ± 0.05 |
| C7 (15% Beeswax) | 0.68 ± 0.02 |
| C8 (5% Paraffin Wax) | 0.58 ± 0.04 |
| C9 (10% Paraffin Wax) | 0.55 ± 0.03 |
| C10 (15% Paraffin Wax) | 0.52 ± 0.05 |
| C11 (5% Corn Starch) | 0.77 ± 0.03 |
| C12 (10% Corn Starch) | 0.91 ± 0.04 |
| C13 (15% Corn Starch) | 1.62 ± 0.07 |
| ANOVA | |
| Post-hoc test (pair-wise comparison) | |
| PEG 6000 | C1 and C3 * |
| Beeswax | C1 and C7 * |
| Paraffin wax | C1 and C10 * |
| Corn Starch | C1 and C11 * |
| 15% Additive | C4 and C7 * |
* p < 0.05.
Figure 1The relationship between FMT hardness and percentage of the added additive. Mean ± SD, n = 6.
Figure 2The relationship between (a) FMT in vitro disintegration time and the percentage of added additive; (b) FMT in situ disintegration time and percentage of added additive; (c) FMT in vitro disintegration time in artificial saliva and percentage of added additive. Mean ± SD, n = 6.
Results of in vitro disintegration time, in situ disintegration time, and in vitro disintegration time in artificial saliva of various formulations/additives.
| Formulation | In Vitro Disintegration Time (s) | In Situ Disintegration Time (s) | In Vitro Disintegration Time in Artificial Saliva (s) |
|---|---|---|---|
| C1 (0% additive) | 94.17 ± 3.19 | 51.17 ± 4.45 | 80.50 ± 3.73 |
| C2 (5% PEG6000) | 91.17 ± 4.07 | 50.83 ± 4.62 | 83.67 ± 4.23 |
| C3 (10% PEG6000) | 100.17 ± 3.60 | 57.00 ± 4.98 | 88.67 ± 3.56 |
| C4 (15% PEG6000) | 104.67 ± 3.78 | 64.17 ± 5.46 | 95.33 ± 5.28 |
| C5 (5% Beeswax) | 110.83 ± 4.36 | 71.83 ± 5.49 | 97.00 ± 4.29 |
| C6 (10% Beeswax) | 161.17 ± 4.36 | 132.67 ± 7.39 | 144.50 ± 5.24 |
| C7 (15% Beeswax) | 233.67 ± 9.42 | 205.17 ± 3.19 | 194.83 ± 6.88 |
| C8 (5% Paraffin Wax) | 105.50 ± 4.28 | 70.00 ± 4.00 | 92.50 ± 4.23 |
| C9 (10% Paraffin Wax) | 127.17 ± 5.64 | 93.83 ± 4.45 | 111.50 ± 4.85 |
| C10 (15% Paraffin Wax) | 215.33 ± 6.50 | 182.00 ± 5.83 | 176.33 ± 5.24 |
| C11 (5% Corn Starch) | 86.50 ± 4.37 | 47.50 ± 3.39 | 77.67 ± 3.88 |
| C12 (10% Corn Starch) | 60.67 ± 3.72 | 42.83 ± 2.79 | 60.50 ± 5.36 |
| C13 (15% Corn Starch) | 48.50 ± 4.97 | 38.50 ± 2.95 | 46.00 ± 4.52 |
| ANOVA | |||
| Additives Post-hoc test (pair-wise comparison) | |||
| PEG6000 | C1 and C4 ( | C1 and C4 * | C1 and C4 * |
| Beeswax | C1 and C5 * | C1 and C5 * | C1 and C5 * |
| Paraffin Wax | C1 and C8 * | C1 and C8 * | C1 and C8 * |
| Corn Starch | C1 and C12 * | C1 and C12 * | C1 and C12 * |
| 15% Additive | C4 and C7 * | C4 and C7 * | C4 and C7 * |
* p < 0.05.
The final formulation of cocoa butter-based FMT incorporated with taste-masked dapoxetine.
| Ingredient | Weight (mg/tablet) |
|---|---|
| Kyron T-134/Dapoxetine (0.75:0.25) | 120 |
| Cocoa butter | 425 |
| Corn starch | 75 |
| Ammonium glycyrrhizinate | 30 |
Figure 3Mean dissolution profiles of the final formulation of cocoa butter-based FMT and the innovator product (Priligy) in 0.1 M HCl medium. Mean ± SD, n = 6.
The results of physical properties and drug content after storage at 30 °C for 12 months.
| Parameter | Time (Month) | ANOVA | |||
|---|---|---|---|---|---|
| (A) 0 | (B) 3 | (C) 6 | (D) 12 | ||
| Hardness * (kg) | 2.93 ± 0.22 | 2.96 ± 0.24 | 2.96 ± 0.23 | 2.98 ± 0.22 | |
| Weight * (mg) | 651.20 ± 2.30 | 651.50 ± 1.43 | 651.60 ± 2.07 | 651.70 ± 1.89 | |
| Thickness * (mm) | 10.10 ± 0.06 | 10.16 ± 0.06 | 10.15 ± 0.05 | 10.12 ± 0.05 | |
| Friability * (%) | 0.35 | 0.36 | 0.34 | 0.35 | - |
| In vitro disintegration time ** (s) | 151.67 ± 6.98 | 153.00 ± 5.33 | 152.67 ± 3.98 | 154.83 ± 6.08 | |
| In situ disintegration time ** (s) | 94.33 ± 3.98 | 97.00 ± 3.69 | 94.67 ± 5.16 | 96.17 ± 3.97 | |
| In vitro disintegration time in artificial saliva ** (s) | 123.83 ± 4.40 | 124.67 ± 3.50 | 123.83 ± 3.82 | 124.83 ± 3.76 | |
| Drug content * (%) | 100.56 ± 1.04 | 100.11 ± 1.22 | 100.98 ± 0.98 | 99.89 ± 0.89 | |
* Mean of ten FMTs was used. ** Mean of six FMTs was used.